|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Cancer and Leukemia Group B National Cancer Institute (NCI) |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00022581 |
Purpose
RATIONALE: Thalidomide may stop the growth of non-Hodgkin's lymphoma by stopping blood flow to the tumor.
PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have relapsed or refractory low-grade non-Hodgkin's lymphoma.
| Condition | Intervention | Phase |
|
Lymphoma |
Drug: thalidomide |
Phase II |
| MedlinePlus related topics: | Cancer Lymphoma |
| Drug Information available for: | Thalidomide |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label |
| Official Title: | A Phase II Trial of Thalidomide (NSC# 66847, IND# 48832) for Patients With Relapsed or Refractory Low Grade Non-Hodgkin's Lymphoma |
| Study Start Date: | July 2001 |
OBJECTIVES:
OUTLINE: Patients receive oral thalidomide once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 months for 2 years and then annually for 3 years.
PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study.
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed relapsed or refractory low-grade non-Hodgkin's lymphoma of 1 of the following subtypes:
Bidimensionally measurable disease
The following are not considered measurable:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Neurologic:
Other:
Regardless of fertility status:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
Contacts and Locations| United States, California | |||||
| Kaiser Permanente Medical Office -Vandever Medical Office | Recruiting | ||||
| San Diego, California, United States, 92120 | |||||
| Contact: Han A. Koh 619-528-2596 | |||||
| United States, Indiana | |||||
| CCOP - Northern Indiana CR Consortium | Recruiting | ||||
| South Bend, Indiana, United States, 46601 | |||||
| Contact: Rafat H. Ansari, MD, FACP 574-234-5123 | |||||
| Center for Cancer Therapy at LaPorte Hospital and Health Services | Recruiting | ||||
| La Porte, Indiana, United States, 46350 | |||||
| Contact: Rafat H. Ansari, MD, FACP 574-234-5123 | |||||
| Memorial Hospital of South Bend | Recruiting | ||||
| South Bend, Indiana, United States, 46601 | |||||
| Contact: Clinical Trials Office - Memorial Hospital of South Bend 800-284-7370 | |||||
| Howard Community Hospital | Recruiting | ||||
| Kokomo, Indiana, United States, 46904 | |||||
| Contact: Rafat H. Ansari, MD, FACP 574-234-5123 | |||||
| Elkhart General Hospital | Recruiting | ||||
| Elkhart, Indiana, United States, 46515 | |||||
| Contact: Rafat H. Ansari, MD, FACP 574-234-5123 | |||||
| Saint Joseph Regional Medical Center | Recruiting | ||||
| South Bend, Indiana, United States, 46617 | |||||
| Contact: Rafat H. Ansari, MD, FACP 574-234-5123 | |||||
| South Bend Clinic | Recruiting | ||||
| South Bend, Indiana, United States, 46617 | |||||
| Contact: Rafat H. Ansari, MD, FACP 574-234-5123 | |||||
| United States, Kansas | |||||
| Johnson County Radiation Therapy | Recruiting | ||||
| Overland Park, Kansas, United States, 66210 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Lawrence Memorial Hospital | Recruiting | ||||
| Lawrence, Kansas, United States, 66044 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Menorah Medical Center | Recruiting | ||||
| Overland Park, Kansas, United States, 66209 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Shawnee Mission Medical Center | Recruiting | ||||
| Shawnee Mission, Kansas, United States, 66204 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| United States, Michigan | |||||
| Lakeland Regional Cancer Care Center - St. Joseph | Recruiting | ||||
| St. Joseph, Michigan, United States, 49085 | |||||
| Contact: Rafat H. Ansari, MD, FACP 574-234-5123 | |||||
| United States, Missouri | |||||
| CCOP - Kansas City | Recruiting | ||||
| Kansas City, Missouri, United States, 64131 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Heartland Regional Medical Center | Recruiting | ||||
| Saint Joseph, Missouri, United States, 64506 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Independence Regional Health Center | Recruiting | ||||
| Independence, Missouri, United States, 64050 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Kansas City Cancer Center at St. Joseph's Medical Mall | Recruiting | ||||
| Kansas City, Missouri, United States, 64114 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Radiation Oncology Associates of Kansas City at Northland Radiation Oncology Center | Recruiting | ||||
| Kansas City, Missouri, United States, 64154 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Parvin Radiation Oncology | Recruiting | ||||
| Kansas City, Missouri, United States, 64116 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| North Kansas City Hospital | Recruiting | ||||
| Kansas City, Missouri, United States, 64116 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Research Medical Center | Recruiting | ||||
| Kansas City, Missouri, United States, 64132 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Saint Luke's Cancer Institute at Saint Luke's Hospital | Recruiting | ||||
| Kansas City, Missouri, United States, 64111 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | Recruiting | ||||
| Saint Louis, Missouri, United States, 63110 | |||||
| Contact: Nancy L. Bartlett, MD 314-362-5654 | |||||
| St. Joseph Medical Center | Recruiting | ||||
| Kansas City, Missouri, United States, 64114 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| Truman Medical Center - Hospital Hill | Recruiting | ||||
| Kansas City, Missouri, United States, 64108 | |||||
| Contact: Rakesh Gaur, MD 816-823-0555 | |||||
| United States, North Carolina | |||||
| Duke Comprehensive Cancer Center | Recruiting | ||||
| Durham, North Carolina, United States, 27710 | |||||
| Contact: Clinical Trials Office - Duke Comprehensive Cancer Center 888-275-3853 | |||||
| Pardee Memorial Hospital | Recruiting | ||||
| Hendersonville, North Carolina, United States, 28791 | |||||
| Contact: James E. Radford, MD 828-692-8045 | |||||
| Cancer and Leukemia Group B |
| National Cancer Institute (NCI) |
| Study Chair: | David L. Grinblatt, MD | Evanston Northwestern Healthcare - Evanston Hospital |
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
|
Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD; Cancer and Leukemia Group B. Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol. 2008 Feb;140(3):313-9.
  |
|
Grinblatt DL, Johnson J, Niedzwicki D, et al.: Phase II study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (Sll): CALGB study 50002. [Abstract] Blood 104 (11): A-3284, 2004.
  |
| Study ID Numbers: | CDR0000068832, CALGB-50002 |
| First Received: | August 10, 2001 |
| Last Updated: | December 2, 2008 |
| ClinicalTrials.gov Identifier: | NCT00022581 |
| Health Authority: | Unspecified |
|
|
|
|
|